Applications Open June 25 for Early-Stage Biotech Companies Developing Next-Generation Therapeutics and Platform Technologies

SHANGHAI, June 25, 2026 /PRNewswire/ — ATLATL Innovation Center (“ATLATL”), a global innovation platform for life science research and development, and Samsung Bioepis Co., Ltd., today announced the launch of the Samsung Bioepis Innovation Prize C-Lab Outside (Innovation Prize), an open innovation initiative designed to identify and support promising early-stage biotech companies across the Asia-Pacific region.

Applications for the Innovation Prize will open on June 25, 2026.

The program seeks innovative startups and emerging biotech companies working in the following therapeutic areas:

OncologyImmunology & Inflammation (I&I)Metabolic Disease

Areas of particular interest include:

Novel/New Mechanisms of Action (MoA)-based Antibody-Drug Conjugate (ADC)/ X-Drug Conjugates (XDC) (i.e., Payload, Linker, Conjugation)Antibody Engineering TechnologyNew Modality (Biologics)Peptide (Design Engineering, Long-acting Peptide)Novel Target Discovery Platform

Selected companies will gain access to ATLATL’s world-class laboratory infrastructure, entrepreneurial resources, and industry mentorship. In addition, awardees will have the opportunity to engage with Samsung Bioepis through its open innovation platform, enabling scientific collaboration, technology assessment, and potential future partnership opportunities. Together, these resources are designed to accelerate innovation and support the translation of promising technologies toward commercialization.

“Innovation thrives when visionary science is matched with the right support and opportunities,” said Min Jeong Seo, Vice President and Leader of Open Innovation Team at Samsung Bioepis. “Through the Innovation Prize, we are seeking to empower promising biotech entrepreneurs and researchers who are advancing novel approaches to address unmet medical needs. By fostering collaboration across the Asia-Pacific region, we hope to help accelerate scientific innovation and contribute to a strong ecosystem for the development of future medicines.”

“Great science alone does not create successful biotech companies,” said Dr. PC Zhu, Founder and CEO of ATLATL. “Innovators need access to world-class infrastructure, R&D ecosystem, experienced mentors, strategic partners, and capital to move forward. By bringing together Samsung Bioepis’ global development expertise and ATLATL’s innovation ecosystem, we hope to provide early-stage biotech entrepreneurs with the resources and support needed to accelerate innovation and deliver meaningful impact to patients.”

The Samsung Bioepis Innovation Prize C-Lab Outside reflects both organizations’ commitment to advancing open innovation and supporting the next generation of biotechnology entrepreneurs. By bringing together scientific talent, development expertise, and critical infrastructure, the program aims to accelerate the translation of breakthrough research into transformative therapies for patients worldwide. The Innovation Prize is also part of Samsung Bioepis C-Lab Outside, Samsung Bioepis’ open innovation program designed to discover, nurture, and collaborate with competent and prospective biotech ventures and startups in and outside of Korea.

About ATLATL

As a global innovation platform for life science research and development, ATLATL has established research centers in Beijing, Shanghai, Shenzhen, Singapore, Hong Kong, and other strategic locations.

ATLATL provides clients with comprehensive research and development services covering various stages, including in vitro drug screening, in vivo disease model establishment, and efficacy evaluation. ATLATL also supports key applications such as large molecule, small molecule, nucleic acid drugs, gene and cell therapy, drug delivery, as well as cutting-edge fields like multi-omics, gene editing, organoids, and organ-on-a-chip. Additionally, ATLATL provides an outstanding experimental environment and professional operational management for scientific researchers.

Through in-depth cooperation with leading global enterprises and research institutions, ATLATL continuously integrates research and development resources and promotes the sharing of new technologies. With advanced systematic research and development models, ATLATL accelerates the engineering process of life sciences, enabling scientific research results to be rapidly and efficiently translated into clinical practice, and contributing to life science innovation and public health on a global level.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/atlatl-and-samsung-bioepis-launch-samsung-bioepis-innovation-prize-c-lab-outside-to-accelerate-early-stage-biotech-innovation-across-asia-pacific-302809136.html

SOURCE ATLATL

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

VANCOUVER, BC, June 24, 2026 /CNW/ – Light AI Inc. (“Light AI” or the “Company”) (CBOE CA: ALGO) (FSE: OHC) (OTCQB: OHCFF), a digital healthcare technology company focused on developing artificial intelligence (“AI”) health diagnostic solutions, is pleased to announce, further to its news releases dated May 21, 2026 and June 19, 2026, the appointment of Dallas Fontaine to the board of directors of the Company (the “Board”) as the nominee of MV Capital LP (the “Investor”) pursuant to the investor rights agreement entered into in connection with the Company’s recently completed C$5,000,000 secured convertible debenture unit financing.

Dallas Fontaine – Board Director: Mr. Dallas Fontaine is an entrepreneur, technology executive, and investor with extensive experience scaling technology businesses, driving revenue growth, and supporting emerging companies through commercialization and capital formation. He currently serves as Chief Executive Officer of Mountain Vista Capital, where he leads investment and strategic advisory initiatives focused on high-growth technology companies.

Mr. Fontaine is also Co-Founder of ScaleLabs.dev, a software development and innovation company that partners with startups and growth-stage organizations to accelerate product development and market execution. Throughout his career, he has held leadership positions across technology, sales, operations, and business development, helping companies navigate rapid growth and strategic transformation.

Previously, Mr. Fontaine served as Director of Sales at CTO.ai, where he worked with enterprise customers to accelerate software development workflows and operational efficiency through automation technologies. He has also held executive leadership positions in family-owned and private enterprises, overseeing operations, revenue growth initiatives, and organizational expansion.

Mr. Fontaine brings to Light AI a combination of capital markets experience, operational leadership, technology commercialization expertise, and strategic growth execution. His background in scaling innovative technology companies and working closely with founders, investors, and management teams will support Light AI’s transition from development-stage operations toward regulatory approvals, commercialization, and long-term shareholder value creation.

“We are pleased to welcome Dallas Fontaine to the Board of Directors of Light AI,” said John R. Luna, Chief Executive Officer of Light AI Inc. “Dallas brings valuable experience in technology innovation, business growth, capital markets, and scaling emerging companies. As we advance toward commercialization of our QuickScan™ platform and continue executing on our strategic objectives, his perspective and expertise will be an important addition to our Board.”

“On behalf of the Company, I would also like to thank MV Capital LP for its confidence in Light AI through its participation in our recently completed secured convertible debenture unit financing. We look forward to working closely with Dallas as MV Capital’s representative on the Board and value the partnership and support of MV Capital as we pursue our mission of transforming healthcare diagnostics through artificial intelligence and machine learning software.”

About Light AI Inc. (CBOE CA: ALGO / FSE: OHC / OTCQB: OHCFF)

Light AI Inc. is a technology company focused on developing artificial intelligence health screening and diagnostic solutions. Light AI QuickScan™ is a technology platform which represents the next generation of patient management: it applies AI algorithms to compatible smart device images, starting with images of Strep A and anticipated expansion with other medical conditions, to identify the disease in seconds. Its patented, app-based solution requires no swabs, lab tests or proprietary hardware of any kind as its computing platform includes the 4.5 billion smartphones that exist in the world today. Light AI is at the forefront of developing innovative screening and diagnostic solutions aimed at improving healthcare delivery worldwide. Its cutting-edge AI powered technology offers rapid, accurate, and cost-effective screening and diagnostic tools designed to address critical healthcare challenges.

In pre-FDA validation studies, Light AI’s algorithm demonstrated remarkable accuracy in differentiating between viral and bacterial pharyngitis, specifically targeting Group A Streptococcus (“GAS”). The algorithm achieved a 96.57% accuracy rate and attained a Negative Predictive Value of 100%, indicating its high reliability in confirming the absence of Streptococcus A infection. Viral and GAS pharyngitis affects over 600 million people annually worldwide. If left untreated, GAS pharyngitis can lead to serious complications such as Rheumatic Heart Disease (“RHD”), which imposes a global economic burden exceeding $1 trillion annually. Light AI’s technology offers a significant advancement in the accurate and timely identification of GAS pharyngitis, potentially reducing the incidence of RHD and its associated costs. Light AI’s approach to applying AI to smart device images can be expanded to other medical conditions, as well as other areas of analysis. Light AI’s vision is to combine the Light AI QuickScan™ software platform with AI in-the-Cloud to create a Digital Clinical Lab that provides quick and accessible diagnosis for countless conditions that today require expensive and time-consuming imaging or lab processes.

ON BEHALF OF THE COMPANY

“John R. Luna”
Chief Executive Officer
Telephone: 1-(888) 804-9459
Email: jluna@light.ai

Website: https://light.ai/
LinkedIn: LinkedIn/company/Light AI
X (Formerly Twitter): @lightaihealth

Forward-Looking Information:

This news release contains statements and information that, to the extent that they are not historical fact, constitute “forward-looking information” within the meaning of applicable securities legislation, including statements relating to the anticipated contributions of Dallas Fontaine as a director and the advancement of the Company’s business. Forward-looking information is based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, but not limited to, statements relating to the Company’s financial performance, business development, results of operations, and those listed in filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedarplus.ca). Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking statement speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company does not undertake any obligation to update any forward-looking information to reflect information, events, results, circumstances or otherwise after the date hereof or to reflect the occurrence of unanticipated events, except as required by law including securities laws.

SOURCE Light AI Inc.

New endorsement affirms D&O coverage for organizations engaged in cryptocurrency, stablecoins, and other digital asset operations

SAN FRANCISCO, June 24, 2026 /PRNewswire/ — Corgi, the AI-native insurance carrier built for startups, today announced the launch of its Digital Assets Coverage Endorsement, a new policy enhancement designed to provide greater clarity and certainty for companies operating in the digital asset ecosystem.

The endorsement expressly affirms coverage under Directors and Officers (D&O) Liability Insurance for claims arising from organizations who have digital asset operations, including activities involving cryptocurrencies.

As digital asset businesses continue to mature, many founders and executives face uncertainty around how traditional insurance policies respond to emerging technologies and business models. The Digital Assets Coverage Endorsement is designed to address that uncertainty by explicitly recognizing digital asset operations within the scope of covered activities.

“Digital asset companies have spent years navigating an insurance market that often treated blockchain businesses as exceptions,” said Emily Yuan, CEO and co-founder of Corgi. “We believe insurance should evolve alongside innovation. This endorsement provides founders, boards, and investors with greater confidence that their insurance coverage reflects the realities of how modern technology companies operate.”

The endorsement defines digital assets broadly to include blockchain-based and distributed ledger-based tokens, cryptocurrencies, stablecoins, and other virtual assets, regardless of how they are classified under applicable law.

Importantly, the endorsement clarifies that an organization’s participation in digital asset operations, by itself, does not trigger policy exclusions. Coverage remains subject to all other policy terms, conditions, exclusions, retentions, and limits.

The launch reflects Corgi’s continued expansion into emerging technology risks and its commitment to building insurance products that align with the needs of innovative companies.

About Corgi
Corgi is an AI-native insurance carrier built for startups and high-growth technology companies. By combining proprietary underwriting technology, in-house claims handling, and modern insurance infrastructure, Corgi helps businesses secure coverage faster and manage risk more effectively as they scale.

Media Contact

Erika Lee

erika@corgi.insure

View original content:https://www.prnewswire.com/news-releases/corgi-launches-digital-assets-coverage-endorsement-for-directors-and-officers-liability-insurance-302809823.html

SOURCE Corgi